| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Trevi Therapeutics Inc. | Haduvio - (PRISM) | Prurigo Nodularis (PN) | Phase 2/3 | Data Released | Oral | #N/A |
| Trevi Therapeutics Inc. | Haduvio (oral nalbuphine ER) - (RIVER) | Refractory chronic cough (RCC) | Phase 2b | Trial Planned | Oral | Respiratory |
| Trevi Therapeutics Inc. | Nalbuphine ER - (CORAL) | Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) | Phase 2b | Data Released | Oral | Respiratory |
| Trevi Therapeutics Inc. | Haduvio (oral nalbuphine ER) - (RIVER) | Refractory chronic cough (RCC) | Phase 2b | Trial Planned | Oral | Respiratory |
| Trevi Therapeutics Inc. | Nalbuphine ER - (CORAL) | Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF) | Phase 2b | Data Released | Oral | Respiratory |
| Tricida Inc. | TRC101 - (VALOR-CKD) | Chronic Kidney Disease | Phase 3 | Oral | N/A | |
| Tricida Inc. | TRC101 - (VALOR-CKD) | Chronic Kidney Disease | Phase 3 | Oral | N/A | |
| TScan Therapeutics Inc. | OmnImmune | Acute myeloid leukemia (AML) | Phase 2b | Trial Completed | Intravenous | Oncology |